8-K: Theravance Biopharma Q2: Strong Sales, Cash Boost

Theravance Biopharma reports significant Q2 2025 financial improvements driven by YUPELRI sales growth and a $225 million TRELEGY royalty monetization.

Summary

• Total revenue for Q2 2025 was $26.2 million, up from $14.3 million in Q2 2024.
• Net income for Q2 2025 was $54.8 million, a significant improvement from a net loss of $16.5 million in Q2 2024.
• Cash, cash equivalents, and marketable securities totaled $338.8 million as of June 30, 2025, up from $88.4 million at December 31, 2024.
• YUPELRI (revefenacin) U.S. net sales, recognized by Viatris, increased 22% year-over-year to $66.3 million in Q2 2025.
• A $7.5 million milestone payment was received from Viatris for YUPELRI's approval in China.
• The company completed the sale of its remaining TRELEGY ELLIPTA royalty interest to GSK for a one-time cash payment of $225 million, resulting in a net gain of $75.1 million.
• Enrollment for the pivotal Phase 3 CYPRESS study of ampreloxetine is on track to complete by late summer, with top-line data expected approximately six months later.
• TRELEGY global net sales by GSK were approximately $1.1 billion in Q2 2025 and $2.0 billion year-to-date, on track to trigger a $50 million milestone from Royalty Pharma in 2025.

Sentiment

Score: 8

Explanation: The filing indicates strong financial performance driven by a significant one-time gain from asset monetization, robust growth in key product sales (YUPELRI), and positive progress in the lead clinical program (ampreloxetine). The substantial increase in cash and debt-free status provide significant financial flexibility. While a non-GAAP loss persists, the overall trajectory and strategic execution are highly positive.

Positives

• Net income of $54.8 million in Q2 2025, a substantial turnaround from a $16.5 million net loss in Q2 2024.
• Cash, cash equivalents, and marketable securities significantly increased to $338.8 million, providing a strong balance sheet with no debt.
• YUPELRI U.S. net sales grew 22% year-over-year to $66.3 million, demonstrating continued commercial growth.
• YUPELRI customer demand increased 4% for the quarter, and hospital channel doses grew 31% year-over-year, reaching a new market share high of 20.4%.
• Received a $7.5 million milestone payment for YUPELRI's approval in China.
• Successful monetization of the TRELEGY royalty interest for $225 million cash, enhancing financial flexibility and shareholder value.
• TRELEGY sales are on track to trigger a $50 million milestone payment from Royalty Pharma in 2025 and a potential $100 million milestone in 2026.
• Ampreloxetine's pivotal Phase 3 CYPRESS study enrollment is on track for completion by late summer, indicating progress in the lead pipeline asset.

Negatives

• Income tax expense increased significantly to $18.4 million in Q2 2025 from $1.3 million in Q2 2024, primarily due to the net gain on the TRELEGY royalty sale.
• While non-GAAP net loss from operations improved, the company still reported a non-GAAP net loss of $4.2 million in Q2 2025.

Risks

• Factors could increase cash requirements or expenses beyond expectations, adversely affecting profitability.
• Uncertainty exists regarding whether future milestone thresholds can be achieved.
• Delays or difficulties may occur in commencing, enrolling, or completing clinical studies.
• Results from clinical or non-clinical studies could indicate product candidates are unsafe, ineffective, or not differentiated.
• Regulatory authorities may make unfavorable decisions.
• Dependence on third parties to conduct clinical studies, and to discover, develop, manufacture, and commercialize products.
• Delays or failure to achieve and maintain regulatory approvals for product candidates.
• Risks associated with establishing and maintaining sales, marketing, and distribution capabilities.
• Ability to protect and enforce intellectual property rights may be challenged.
• Volatility and fluctuations in the trading price and volume of the company's shares.
• General economic and market conditions could adversely impact the business.

Future Outlook

The company reiterates its full-year 2025 financial guidance, expecting R&D expenses (excluding share-based compensation) between $32 million and $38 million, and SG&A expenses (excluding share-based compensation) between $50 million and $60 million. Full-year share-based compensation expenses are projected to be $18 million to $20 million. Non-GAAP Net Income (Loss) from Operations and Cash Burn in 2025 are expected to be similar to 2024 levels, excluding one-time revenue and income items. Enrollment for the pivotal Phase 3 CYPRESS study of ampreloxetine is expected to complete by late summer, with top-line data anticipated approximately six months thereafter. The company is advancing pre-launch activities for ampreloxetine in preparation for potential approval and plans to file an NDA for full approval if Phase 3 results are supportive. TRELEGY sales are on track to trigger a $50 million milestone from Royalty Pharma in 2025 and a $100 million milestone in 2026. The Strategic Review Committee will continue to evaluate alternatives to enhance shareholder value, focusing on disciplined capital allocation and returning excess cash to shareholders.

Management Comments

• "Strong execution across our business defined the second quarter, driven by commercial growth, disciplined operations, and continued progress on ampreloxetine."
• "YUPELRI posted another strong quarter in the U.S., and its recent approval in China triggered a $7.5 million milestone payment."
• "With the completion of the strategic monetization of our TRELEGY royalty interest, which brought in $225 million, these accomplishments have meaningfully strengthened our business."
• "We enter the second half of 2025 with momentum and a clear focus on ampreloxetine. We remain on track for completing the enrollment in our pivotal Phase 3 CYPRESS study in late summer, and continue to prepare for reporting top-line data approximately six months later."

Industry Context

The biopharmaceutical industry continues to focus on developing treatments for chronic respiratory diseases like COPD and rare neurological disorders such as Multiple System Atrophy (MSA) with neurogenic orthostatic hypotension (nOH). Theravance Biopharma's YUPELRI, a once-daily nebulized LAMA, addresses a specific segment of the COPD market, particularly patients who require or prefer nebulized therapy. The progress of ampreloxetine for nOH in MSA patients positions the company in the orphan drug space, targeting an underserved patient population with a potential first-in-class therapy. The successful monetization of the TRELEGY royalty reflects a broader industry trend of companies optimizing asset portfolios and leveraging non-core assets to strengthen balance sheets and fund pipeline development.

Comparison to Industry Standards

• YUPELRI's hospital market share reached a new high of 20.4%, indicating strong adoption within a key initiation setting for COPD maintenance therapy.
• Ampreloxetine is positioned as a potential first-in-class, once-daily treatment for symptomatic nOH in MSA patients, differentiating it from existing therapies like Droxidopa and Midodrine which require multiple daily doses, titration, and have established safety concerns such as increased risk of supine hypertension, which has not been observed with ampreloxetine in clinical studies to date.
• The company targets approximately 40,000 underserved patients with symptomatic nOH due to MSA, highlighting a significant unmet medical need compared to the current treatment landscape where 65% of patients remain symptomatic despite available therapies.

Corporate Governance

Legal Proceedings

• Status of patent infringement litigation initiated by the company and its partner against certain generic companies in federal district courts.

Related Party Transactions

• Sale of remaining royalty interest in Trelegy Ellipta to GSK for a one-time cash payment of $225 million.
• Collaboration agreement with Viatris for YUPELRI, where Viatris leads commercialization and the company co-promotes under a 35%/65% profit and loss sharing arrangement.
• Eligibility to receive up to an additional $150 million in near-term TRELEGY sales milestones from Royalty Pharma pursuant to an Equity Purchase and Funding Agreement dated July 13, 2022.

Stakeholder Impact

• **Shareholders**: Significant increase in cash position and net income, successful asset monetization, and commitment to evaluating options for returning excess cash, potentially leading to increased shareholder value.
• **Patients (COPD)**: Continued availability and growth of YUPELRI, providing a once-daily nebulized LAMA option.
• **Patients (MSA with nOH)**: Progress in ampreloxetine's Phase 3 study offers hope for a potential new, differentiated treatment for an underserved patient population.
• **Partners (Viatris, GSK, Royalty Pharma)**: Continued collaboration and milestone achievements reinforce existing partnerships and potential for future payments.

Next Steps

• Complete enrollment in the pivotal Phase 3 CYPRESS study for ampreloxetine by late summer.
• Report top-line data from the CYPRESS study approximately six months after enrollment completion.
• Advance pre-launch activities for ampreloxetine across medical affairs and commercial functions.
• Prepare for potential NDA filing for ampreloxetine for full approval in symptomatic nOH in MSA patients, if Phase 3 results are supportive.
• Achieve full year 2025 global net sales of TRELEGY exceeding ~$3.4 billion to trigger a $50 million milestone from Royalty Pharma.
• Achieve full year 2026 global net sales of TRELEGY exceeding ~$3.5 billion to trigger a $100 million milestone from Royalty Pharma.
• The Strategic Review Committee will continue to evaluate a range of alternatives to further enhance shareholder value and return excess cash to shareholders.

Key Dates

Recommendation

The company's Q2 2025 results demonstrate robust financial health, driven by a substantial cash infusion from the TRELEGY royalty sale and strong commercial performance of YUPELRI. The significant increase in cash to $338.8 million with no debt provides exceptional financial flexibility for future investments and potential capital returns. The lead pipeline asset, ampreloxetine, is on track for Phase 3 completion and top-line data within six months, representing a major near-term catalyst with significant market potential in an underserved orphan disease. The company's disciplined capital allocation strategy and ongoing strategic review further enhance shareholder value prospects. These factors, combined with the potential for additional milestone payments, position Theravance Biopharma for strong future growth and make it a compelling investment.

Keywords

Biopharma, COPD, Neurogenic Orthostatic Hypotension, Multiple System Atrophy, YUPELRI, Ampreloxetine, TRELEGY, Clinical Trials, Phase 3, Orphan Drug, Royalty Monetization, Financial Results, Pharmaceuticals, Drug Development